Adefovir dipivoxil

SKU: orb1307797

Description

Adefovir dipivoxil (GS 0840) is an orally bioavailable prodrug of adefovir, an adenosine nucleotide analog functioning as a reverse transcriptase inhibitor. It is utilized in research for its antiviral activity against HBV, herpesviruses, and HIV in both in vitro and in vivo experimental models.

Research Area

Cell Biology, Infectious Disease & Virology, Metabolism Research, Molecular Biology, Signal Transduction

Key Properties

• CAS Number: 142340-99-6
• MW: 501.47
• Purity: 99.80%
• Formula: C₂₀H₃₂N₅O₈P
• SMILES: CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C(N)N=CN=C12)OCOC(=O)C(C)(C)C
• Target: Virus Protease,ATM/ATR,Endogenous Metabolite,HBV,Reverse Transcriptase,HSV,DNA/RNA Synthesis,CDK
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:3.3 mg/mL (6.58 mM);DMSO:93 mg/mL (185.45 mM);H2O:< 1 mg/mL (insoluble or slightly soluble);Ethanol:93 mg/mL (185.45 mM)

Bioactivity

• In Vivo:
  In the duck HBV (DHBV) model, Adefovir dipivoxil, when used in combination with other nucleoside analogs (Lamivudine, Entecavir, Emtricitabine [FTC], and Telbivudine [L-dT]), exhibits superior antiviral effects compared to monotherapy. Adefovir dipivoxil effectively inhibits viral CCC DNA both in vitro and in vivo within the same model. Notably, Adefovir retains significant anti-HBV activity soon after being introduced to cells. Its use in conjunction with Lamivudine, FTC, or L-dT demonstrates cumulative effects, while synergy is observed when combined with Entecavir or Tenofovir. Additionally, Adefovir dipivoxil suppresses the activity of the polymerase by inhibiting the transcription of the pre-genomic RNA. The dosage of Adefovir dipivoxil is correlated with its ability to suppress the release of the virus in culture supernatants and the synthesis of viral DNA within cells.
• In Vitro:
  Compared to the placebo control group with 5.3 log10 GE/mL, Adefovir Dipivoxil significantly reduced serum HBV DNA levels in transgenic mice to 3.5 log10 genome equivalents (GE) per mL, indicating a marked suppression of the hepatitis B virus. In the liver, Adefovir Dipivoxil's antiviral activity peaked on day 10, achieving hepatitis B virus inhibition endpoints at a dose of 1.0 mg/kg/day. Furthermore, Adefovir Dipivoxil decreased liver HBV DNA to <0.1 picograms of hepatitis B virus per total DNA (picograms/mg) in each transgenic mouse.

Storage & Handling

• Storage: store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Preveon, prodrug, Protein P, Reverse Transcriptase, ReverseTranscriptase, analogue, Adefovir dipivoxil, oral, nucleotide, infection, inhibit, Hepatitis B virus, HBV, Hepsera, Inhibitor, GS 0840, GS0840, GS-0840, Endogenous Metabolite

Compound Identifiers

PubChem CID

60871